Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385841 | 0.90 | RAB9A (0.51) | RAB9ANPC1GAANPSR1MAPT | |
| SCHEMBL15431414 | 0.90 | RAB9A (0.51) | RAB9ANPC1GAANPSR1MAPT | |
| SCHEMBL12094075 | 0.88 | NPSR1 (0.42) | RAB9ANPC1NPSR1MAPTEPHX1 | |
| SCHEMBL10132074 | 0.85 | SMN1; SMN2 (0.52) | NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL25029638 | 0.84 | MME (0.40) | RAB9ANPC1GAANPSR1MAPT | |
| SCHEMBL25030885 | 0.84 | NPSR1 (0.40) | RAB9ANPC1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL26062862 | 0.84 | NPSR1 (0.40) | RAB9ANPC1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL23135471 | 0.83 | NPSR1 (0.53) | RAB9ANPC1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL4761695 | 0.82 | MEN1 (0.39) | NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL4761690 | 0.81 | BTK (0.42) | GAANPSR1MAPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | RAB9A 1697/4885NPC1 4258/4885GAA 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.